1976 - The Company was incorporated under the Companies Act, 1956 on
19th April, as a Private Limited Company as Shasun Chemicals
(Madras) Pvt. Ltd., and was converted into a Public Limited
Company on 21st March 1992.
1993 - The name of the Company was changed to Shasun Chemicals and Drugs
Ltd., on 25th October, in terms of resolution passed under
Section 21 of the Companies Act. Fresh Certificate of
Incorporation was obtained on 26th November.
1994 - The Company recently received the prestigious 'Trishul' award
from CHEMEXCIL for exports during 1990-91.
- The Company's maiden public issue of 15,10,000 equity shares
(out of which 1,00,000 shares were reserved for This Industrial
Credit and Investment Corporation of India Limited and 40,000
shares for employees).
1995 - The Company is embarking on a major expansion during the current
year for increasing the capacity of Ibuprofen & Ranitidine and
for the manufacture of two new drugs.
- The Company has signed a technical collaboration and marketing
agreement with Nagase & Co., Japan, for the manufacture of S-
Ibuprofen, a high value drug.
- The company has commissioned wind mills for generation of power.
The total installed capacity is 1 MW which will effect
substantial savings in energy costs.
- The company has set up a subsidiary - Shasun, Inc., at Boston,
USA, in June, for marketing its products.
1996 - The Company has been awarded the Certificate of Merit for
outstanding export performance for 1993-94 by CHEMEXCIL.
- The Company has obtained the prestigious ISO 9002 certification
from Bureau Veritas Quality International, Switzerland, on
1997 - The Company has signed a technology transfer agreement with
Chirotech, U.K. for the manufacture of 5-Naproxen, an
antinflammatory drug. Chirotech is the technology marketing wing
of Chiroscience, a company engaged in Research & Development of
- Shasun USA Inc. has established itself as a full fledged
marketing arm of the Company for the North American continent.
- The Company allotted 14.5% - 5,00,000 Redeemable Preference
Shares of Rs. 100 each to Industrial Development Bank of India on
private placement basis, to augment long term working capital
- The company has a technical collaboration with Nagase of
Japan which will give an access to S. Ketoprofen, SPBA and
D-Naproxen by a new chiral auxilliary.
1998 - Shasun Chemicals is a Madras-based company engaged in the
manufacture of Ibuprofen, Ranitidine and intermediaries.
1999 - The company has signed technology transfer agreement with Chiro
Tech of UK for the manufacture of S-Naproxen, an inflammatory
drug through the bio-technology route.
- The company had entered into a technological tie-up with
Genpharm for process know-how, for the production of Ranitidine
- The company has entered into an agreement with a Canadian
formulation company for supplying Ranitidine.
- The company is set to increase the capacity of its Cuddalore
plant from 22 tonnes to 45 tonnes per month.
- The agreement, which is officially termed a 'joint venture' by
company officials, is the first of its kind Austin has with any
company around the world.
- The Company has an agreement with Austin Chemical Company of
the US under which Austin would liasie with drug MNCs and get
Shasun contracts for development of molecules.
2000 - The Company manufacturer of bulk drugs and their intermediates,
is all set to enter the formulations segment with its recent
tie-up with the US-based Eastman Chemical Company.
- The Company signing the letter of intent under which Eastman
Chemical Company, USA licence its technology for manufacturing
hydorxyprpylecellulose phthalate, pharmaceutical excipient to the
- The Company has been given the Visveswarayya Industrial Award bys
the All India Manufacturers Organisation.
- The Company has bagged the merit trophy for quality excellence from the
Indian Drug Manufacturers Association.
-Board approves for hiving of its manufacturing unit , manufacturing ibuprofen into a separate joint venture company with a foreign drug major.
-Forms an alliance with Eastman Chemical Co. Ltd of US to license the latters technology for the manufacture of acyrlic emulsion.
-Fire accidents in one of the packing sections of Cuddalore factory.
-Obtaines US FDA approval for its three bulk active pharmaceutical products.
-Enters into alliance with Suven Pharmaceuticals Ltd and Innovasynth Technologies Ltd for drug discovery.
-Enters into a pact with Eli Lilly and Co. for manufacture of API Tuberculosis.
-Brings down the average effective cost of its term loans to 5% from the level of 10% in last year.
-Board approves for the issue and allotment of 9,40,000 shares on a preferential basis.
-US-based Genome Technologies enters into a bioinformatics deal with the company on the heels of cost advantage offered by India.
-GMO Emerging Market Fund acquires 9,10,000 shares amounting to 9.96% of total paid up capital of the company.
-Dr. Ashish Mukherjee has been appointed as the Chief Scientific Officer (CSO).
-Chennai-based bulk drug maker Shasun Chemicals on June 15 announced its strategic alliance with Eastman Chemicals of the US for the development and manufacture of performance chemicals
-Shasun Chemicals signs mfg & supply agreement with Codexis, USA
-Shasun Chemicals enters into an agreement with Alpharma.
- Shasun Chemicals signs technology licensing Agreement with Lundbeck.